Dr. Christopher M. Aderman, M.D.

Medicare patients and services

Medicare patients, 2024

696

Services billed

31,803

Patients’ average age

77

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 35 payments worth $34,089 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Oregon →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $813,258 in research payments for these studies, mostly to the institutions running them.

• A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914
• A phase 2, multicenter, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema
  Kyowa Kirin, Inc.
• Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
  Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503
• CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitre…
  Boehringer Ingelheim International GmbH
• A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
  Regeneron Pharmaceuticals, Inc.
• A phase 2, multicenter, randomized, double-masked, parallel group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related m…
  Kyowa Kirin, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.